Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

• Jennifer Edelmann,
• Jitka Malcikova,
• Jitka Malcikova,
• John C. Riches,
• John C. Riches

Affiliations

Jennifer Edelmann

ClinSciNet - The Clinician Scientist Network, Münsingen, Germany

Jitka Malcikova

Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czechia

Jitka Malcikova

Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia

John C. Riches

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

John C. Riches

Department of Haemato-Oncology, Barts Health NHS Trust, St. Bartholomew’s Hospital, London, United Kingdom